PE-22-28
About
About PE-22-28
PE-22-28 is a synthetic peptide fragment of spadin, a peptide derived from the sortilin proprotein, which acts as an antidepressant through TREK-1 potassium channel blockade — a novel non-monoamine mechanism. Preclinical data shows rapid antidepressant effects comparable to ketamine without dissociative side effects. It is being investigated as a fast-acting antidepressant for treatment-resistant depression.
Science
Mechanism of Action
Selectively inhibits TREK-1 (TWIK-related potassium channel 1) in the raphe nuclei and hippocampus, increasing serotonergic neurotransmission and BDNF expression through a mechanism distinct from SSRIs and entirely independent of monoamine reuptake inhibition.
Dosing
Typical Protocol
Intranasal administration in animal studies; human dosing not yet established. Research stage only.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
No verified providers offering PE-22-28 yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering PE-22-28.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.